Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-10-2009 | Review Article

Molecular imaging of hypoxia with radiolabelled agents

Authors: Gilles Mees, Rudi Dierckx, Christel Vangestel, Christophe Van de Wiele

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2009

Abstract

Tissue hypoxia results from an inadequate supply of oxygen (O₂) that compromises biological functions. Structural and functional abnormalities of the tumour vasculature together with altered diffusion conditions inside the tumour seem to be the main causes of tumour hypoxia. Evidence from experimental and clinical studies points to a role for tumour hypoxia in tumour propagation, resistance to therapy and malignant progression. This has led to the development of assays for the detection of hypoxia in patients in order to predict outcome and identify patients with a worse prognosis and/or patients that would benefit from appropriate treatments. A variety of invasive and non-invasive approaches have been developed to measure tumour oxygenation including oxygen-sensitive electrodes and hypoxia marker techniques using various labels that can be detected by different methods such as positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), autoradiography and immunohistochemistry. This review aims to give a detailed overview of non-invasive molecular imaging modalities with radiolabelled PET and SPECT tracers that are available to measure tumour hypoxia.

Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004;9(Suppl 5):4–9.PubMedCrossRef

Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225–39.PubMedCrossRef

Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266–76.PubMedCrossRef

Höckel M, Schlenger K, Aral B, Mitze M, Schäffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509–15.PubMed

Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149–56.PubMedCrossRef

Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31–9.PubMed

Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285–9.PubMed

Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18–24.PubMedCrossRef

Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941–3.PubMed

10.

Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole. Semin Nucl Med 2007;37:451–61.PubMedCrossRef

11.

Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008;49:129S–48S.PubMedCrossRef

12.

Kubota K, Tada M, Yamada S, Hori K, Saito S, Iwata R, et al. Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue. Eur J Nucl Med 1999;26:750–7.PubMedCrossRef

13.

Rasey JS, Casciari JJ, Hofstrand PD, Muzi M, Graham MM, Chin LK. Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Radiat Res 2000;153:84–92.PubMedCrossRef

14.

Bentzen L, Keiding S, Horsman MR, Grönroos T, Hansen SB, Overgaard J. Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Acta Oncol 2002;41:304–12.PubMedCrossRef

15.

Dubois L, Landuyt W, Haustermans K, Dupont P, Bormans G, Vermaelen P, et al. Evaluation of hypoxia in an experimental rat tumour model by [18F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 2004;91:1947–54.PubMedCrossRef

16.

Troost EGC, Laverman P, Kaanders JHAM, Philippens M, Lok J, Oyen WJG, et al. Imaging hypoxia after oxygenation modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol 2006;80:157–64.PubMedCrossRef

17.

Troost EGC, Laverman P, Philippens MEP, Lok J, van der Kogel AJ, Oyen WJG, et al. Correlation of [18F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 2008;35:1803–11. doi:10.1007/s00259-008-0772-7.

18.

Bentzen L, Keiding S, Horsman MR, Falborg L, Hansen SB, Overgaard J. Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography. Acta Oncol 2000;39:629–37.PubMedCrossRef

19.

Wyss MT, Honer M, Schubiger PA, Ametamey SM. NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging 2006;33:311–8.PubMedCrossRef

20.

Zanzonico P, Campa J, Polycarpe-Holman D, Forster G, Finn R, Larson S, et al. Animal-specific positioning molds for registration of repeat imaging studies: comparative microPET imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors. Nucl Med Biol 2006;33:65–70.PubMedCrossRef

21.

Oswald J, Treite F, Hasse C, Kampfrath T, Mäding P, Schwenzer B, et al. Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: comparison of different tumor cells and primary endothelial cells. Cancer Lett 2007;254:102–10.PubMedCrossRef

22.

Dence CS, Ponde DE, Welch MJ, Lewis JS. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. Nucl Med Biol 2008;35:713–20.PubMedCrossRef

23.

Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133–7.PubMed

24.

Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncoly Biol Phys 1996;36:417–28.PubMed

25.

Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O–H2O. J Nucl Med 2004;45:1851–9.PubMed

26.

Lawrentschuk N, Poon AM, Foo SS, Johns Putra LG, Murone C, Davis ID, et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int 2005;96:540–6.PubMedCrossRef

27.

Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M, et al. FDG—a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 2006;33:1426–31.PubMedCrossRef

28.

Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Kaiser HJ, et al. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer 2007;7:113–22.PubMedCrossRef

29.

Gagel B, Reinartz P, DiMartino E, Zimney M, Pinkawa M, Maneschi P, et al. pO(2) polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004;180:616–22.PubMedCrossRef

30.

Bentzen L, Keiding S, Nordsmark M, Falborg L, Hansen SB, Keller J, et al. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 2003;67:339–44.PubMedCrossRef

31.

Rajendran JG, Wikson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003;30:695–704.PubMed

32.

Rajendran JG, Mankoff DA, O’Sullivan F, Peterson LM, Schwartz DL, Conrad EU, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorideoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245–52.PubMedCrossRef

33.

Cherk MH, Foo SS, Poon AM, Knight SR, Murone C, Papenfuss AT, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET. J Nucl Med 2006;47:1921–6.PubMed

34.

Cher LM, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 2006;47:410–8.PubMed

35.

Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 2006;80:151–6.PubMedCrossRef

36.

Rajendran JG, Schwartz DL, O’Sullivan J, Peterson LM, Ng P, Scharnhorst J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006;12:5435–41.PubMedCrossRef

37.

Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253–60.PubMed

38.

Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 2005;32:1384–91.PubMedCrossRef

39.

Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:2098–104.PubMedCrossRef

40.

Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, et al. [18F] fluoromisonidazole and [18F] fluordeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 2006;6:51–8.PubMedCrossRef

41.

Nehmeh SA, Lee NY, Schröder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:235–42.PubMed

42.

Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A, et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003;30:317–26.PubMedCrossRef

43.

Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106–13.PubMed

44.

Reischl G, Dorow DS, Cullinane C, Katsifis A, Roselt P, Binns D, et al. Imaging of hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA—first small animal PET results. J Pharm Pharm Sci 2007;10:203–11.PubMed

45.

Beck R, Röper B, Carlsen JM, Huisman MC, Lebschi JA, Andratschke N, et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med 2007;48:973–80.PubMedCrossRef

46.

Busk M, Horsman MR, Jakobsen S, Keiding S, van der Kogel AJ, Bussink J, et al. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, pO2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys 2008;70:1202–12.PubMed

47.

Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 2008;35:2294–303. doi:10.1007/s00259-008-0888-9.

48.

Souvatzoglou M, Grosu AL, Röper B, Krause BJ, Beck R, Reischl G, et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging 2007;34:1566–75.PubMedCrossRef

49.

Grosu AL, Souvatzoglu M, Röper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:541–51.PubMed

50.

Rasey JS, Hofstrand PD, Chin LK, Tewson TJ. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999;40:1072–9.PubMed

51.

Barthel H, Wilson H, Collingridge DR, Brown G, Osman S, Luthra SK, et al. In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer 2004;90:2232–42.PubMed

52.

Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, et al. Development of F-18-labeled fluoroerythronitromidazole as a PET agent for imaging tumor hypoxia. Radiology 1995;194:795–800.PubMed

53.

Grönroos T, Eskola O, Lehtiö K, Minn H, Marjamäki P, Bergman J, et al. Pharmacokinetics of [18F]FETNIM: a potential hypoxia marker for PET. J Nucl Med 2001;42:1397–1404.PubMed

54.

Grönroos T, Bentzen L, Marjamäki P, Murata R, Horsman MR, Keiding S, et al. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004;31:513–20.PubMedCrossRef

55.

Tolvanen T, Lehtiö K, Kulmala J, Oikonen V, Eskola O, Bergman J, et al. 18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies. J Nucl Med 2002;43:1674–80.PubMed

56.

Lehtiö K, Oikinen V, Grönroos T, Eskola O, Kalliokoski K, Bergman J, et al. Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitromidazole PET. J Nucl Med 2001;42:1643–52.PubMed

57.

Lehtiö K, Oikonen V, Nyman S, Grönroos T, Roivainen A, Eskola O, et al. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging 2003;30:101–8.PubMedCrossRef

58.

Lehtiö K, Eskola O, Viljanen T, Oikinen V, Grönroos T, Sillanmäki L, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;59:971–82.PubMedCrossRef

59.

Ziemer LS, Evans SM, Kachur AV, Shuman AL, Cardi CA, Jenkins WT, et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med Mol Imaging 2003;30:259–66.PubMed

60.

Yapp DTT, Woo J, Kartono A, Sy J, Oliver T, Skov KA, et al. Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography. BJU Int 2007;99:1154–60.PubMedCrossRef

61.

Komar G, Seppänen M, Eskola O, Lindholm P, Grönroos TJ, Forsback S, et al. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008;49:1944–51.PubMedCrossRef

62.

Mahy P, De Bast M, Leveque PH, Gillart J, Labar D, Marchand J, et al. Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)-N-(3, 3, 3-[18F]trifluoropropyl)-acetamide, [18F]EF3. Eur J Nucl Med Mol Imaging 2004;31:1263–72.PubMedCrossRef

63.

Mahy P, De Bast M, Gillart J, Labar D, Grégoire V. Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis. Eur J Nucl Med Mol Imaging 2006;33:553–6.PubMedCrossRef

64.

Mahy P, De Bast M, de Groot T, Cheguillaume A, Gillart J, Haustermans K, et al. Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-FMISO in rodent tumor models. Radiother Oncol 2008;89:353–60. doi:10.1016/j.radonc.2008.06.008.

65.

Christian N, Bol A, De Bast M, Labar D, Lee J, Mahy P, et al. Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model. Eur J Nucl Med Mol Imaging 2007;34:1348–54.PubMedCrossRef

66.

Dubois L, Landuyt W, Cloetens L, Bol A, Bormans G, Haustermans K, et al. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Eur J Nucl Med Mol Imaging 2009;36:209–18. doi:10.1007/s00259-008-x.

67.

Mahy P, Geets X, Lonneux M, Levêque P, Christian N, De Bast M, et al. Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism. Eur J Nucl Med Mol Imaging 2008;35:1282–9.PubMedCrossRef

68.

Evans SM, Kachur AV, Shiue CY, Hustinx R, Jenkins WT, Shive GG, et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 2000;41:327–36.PubMed

69.

Zanzonico P, O’Donoghue J, Chapman JD, Schneider R, Cai S, Larson S, et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004;31:117–28.PubMedCrossRef

70.

Riedl CC, Brader P, Zanzonico P, Reid V, Woo Y, Wen B, et al. Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort. Eur J Nucl Med Mol Imaging 2007;35:39–46.PubMedCrossRef

71.

Riedl CC, Brader P, Zanzonico PB, Chun YS, Woo Y, Singh P, et al. Imaging hypoxia in orthotopic rat liver tumors with iodine 124-labeled iodoazomycin galactopyranoside PET. Radiology 2008;248:561–70.PubMedCrossRef

72.

Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36:1625–32.PubMed

73.

Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol 1996;23:941–6.PubMedCrossRef

74.

Burgman P, Odonoghue JA, Humm JL, Ling CC. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med 2001;42:170–5.PubMed

75.

Pedersen MW, Holm S, Lund EL, Hojgaard L, Kristjansen PE. Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia 2001;3:80–7.PubMedCrossRef

76.

Hara T, Bansal A, DeGrado TR. Effect of hypoxia on the uptake of [methyl-3H]choline, [1–14C] acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol 2006;33:977–84.PubMedCrossRef

77.

Oswald J, Treite F, Haase C, Kampfrath T, Mäding P, Schwenzer B, et al. Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: comparison of different tumor cells and primary endothelial cells. Cancer Lett 2007;254:102–10.PubMedCrossRef

78.

Dearling J, Flynn A, Sutcliffe-Goulden J, Petrie L, Boden R, Green A, et al. Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. J Nucl Med 2004;45:101–7.PubMed

79.

Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC, et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 2005;62:545–53.PubMed

80.

Scigliano S, Pinel S, Poussier S, Fouyssac F, Plenat F, Karcher G, et al. Measurement of hypoxia using invasive oxygen-sensitive electrode, pimonidazole binding and 18F-FDG uptake in anaemic or erythropoietin-treated mice bearing human glioma xenografts. Int J Oncol 2008;32:69–77.PubMed

81.

Obata A, Yoshimoto M, Kasamatsu S, Naiki H, Takamatsu S, Kashikura K, et al. Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG. Nucl Med Biol 2003;30:529–34.PubMedCrossRef

82.

Tanaka T, Furukawa T, Fujieda S, Kasamatsu S, Yonekura Y, Fujibayashi Y. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nucl Med Biol 2006;33:743–50.PubMedCrossRef

83.

Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003;30:844–50.PubMed

84.

Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008;51:1641–8.PubMedCrossRef

85.

Dierckx RA, Van de Wiele C. FDG uptake, a surrogate of tumour hypoxia? Eur J Nucl Med Mol Imaging 2008;35:1544–9.PubMedCrossRef

86.

Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans 2007;43:4893–902. doi:10.1039/b705989b.

87.

Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155–60.PubMed

88.

Dearling JLJ, Lewis JS, Mullen GED, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 1998;25:788–92.PubMedCrossRef

89.

Dearling JLJ, Lewis JS, Mullen GED, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 2002;7:249–59.PubMedCrossRef

90.

Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999;40:177–83.PubMed

91.

Burgman P, O’Donoghue JA, Welch LJS, MJ HJL, Ling CC. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol 2005;32:623–30.PubMedCrossRef

92.

Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001;42:655–61.PubMed

93.

Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl- bis(N4-methylthiosemicarbazone). J Nucl Med 2006;47:989–98.PubMed

94.

O’Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl- bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, pO2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDU rat tumor models. Int J Radiat Oncol Biol Phys 2005;61:1493–1502.PubMed

95.

Matsumoto KI, Szajek L, Krishna MC, Cook JA, Seidel J, Grimes K, et al. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]fluoromisonidazole positron emission tomography. Int J Oncol 2007;30:873–81.PubMed

96.

Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response—a preliminary report. Int J Radiat Oncol Biol Phys 2003;55:1233–38.PubMed

97.

Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008;49:201–5.PubMedCrossRef

98.

Grigsby PW, Malyapa RS, Higashikubo R, Schwartz JK, Welch MJ, Huettner PC, et al. Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol 2007;9:278–83.PubMedCrossRef

99.

Chao KSC, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:1171–82.PubMedCrossRef

100.

Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 2008;49:1177–82.PubMedCrossRef

101.

Mannan RH, Somayaji VV, Lee J, Mercer JR, Chapman JD, Wiebe LI. Radioiodinated 1-(5-iodo-5-deoxy-β-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. J Nucl Med 1991;32:1764–70.PubMed

102.

Moore RB, Chapman JD, Mercer JR, Mannan RH, Wiebe LI, McEwan AJ, et al. Measurement of PDT-induced hypoxia in Dunning prostate tumors by iodine-123-iodoazomycin arabinoside. J Nucl Med 1993;34:405–13.PubMed

103.

Parliament MB, Chapman JD, Urtasun RC, McEwan AJ, Golberg L, Mercer JR, et al. Non-invasive assessment of human tumour hypoxia with 123I- iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer 1992;65:90–5.PubMed

104.

Groshar D, McEwan AJB, Parliament MB, Urtasun RC, Golberg LE, Hoskinson M, et al. Imaging tumor hypoxia and tumor perfusion. J Nucl Med 1993;34:885–8.PubMed

105.

Lee HC, Kumar P, McEwan AJ, Wiebe LI, Mercer JR. Synthesis, radiolabeling, and biodistribution of putative metabolites of iodoazomycin arabinoside. Nucl Med Biol 2000;27:61–8.PubMedCrossRef

106.

Urtasun RC, Parliament MB, McEwan AJ, Mercer JR, Mannan RH, Wiebe LI, et al. Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside. Br J Cancer Suppl 1996;27:S209–S12.PubMed

107.

Stypinski D, Wiebe LI, McEwan AJ, Schmidt RP, Tam YK, Mercer JR. Clinical pharmacokinetics of 123I-IAZA in healthy volunteers. Nucl Med Commun 1999;20:559–67.PubMedCrossRef

108.

Stypinski D, McQuarrie SA, Wiebe LI, Tam YK, Mercer JR, McEwan AJB. Dosimetry estimations for 123I-IAZA in healthy volunteers. J Nucl Med 2001;42:1418–23.PubMed

109.

Chapman JD, Coia LR, Stobbe CC, Engelhardt EL, Fenning MC, Schneider RF. Prediction of tumour hypoxia and radioresistance with nuclear medicine markers. Br J Cancer Suppl 1996;27:S204–S8.PubMed

110.

Iyer RV, Kim E, Schneider RF, Chapman JD. A dual hypoxic marker technique for measuring oxygenation change within individual tumors. Br J Cancer 1998;78:163–9.PubMedCrossRef

111.

Mannan RH, Mercer JR, Wiebe LI, Kumar P, Somayaji VV, Chapman JD. Radioiodinated azomycin pyranoside (IAZP): a novel non-invasive marker for the assessment of tumor hypoxia. J Nucl Biol Med 1992;36:60–7.PubMed

112.

Iyer RV, Haynes PT, Schneider RF, Movsas B, Chapman D. Marking hypoxia in rat prostate carcinomas with beta-D-[125I]azomycin galactopyranoside and [99mTc]HL-91: correlation with microelectrode measurements. J Nucl Med 2001;42:337–44.PubMed

113.

Saitoh JI, Sakurai H, Suzuki Y, Muramatsu H, Ishikawa H, Kitamoto Y, et al. Correlations between in vivo tumor weight, oxygen pressure, 31P NMR spectroscopy, hypoxic microenvironment marking by beta-D-iodinated azomycin galactopyranoside (beta-D-IAZGP), and radiation sensitivity. Int J Radiat Oncol Biol Phys 2002;54:903–9.PubMed

114.

Linder KE, Chan YW, Cyr JE, Malley MF, Nowotnik DP, Nunn AD. TcO(PnA.O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reduction. J Med Chem 1994;37:9–17.PubMedCrossRef

115.

Kusuoka H, Hashimoto K, Fukuchi K, Nishimura T. Kinetics of a putative hypoxic tissue marker, technetium-99m-nitroimidazole (BMS181321), in normoxic, hypoxic, ischemic and stunned myocardium. J Nucl Med 1994;35:1371–6.PubMed

116.

Shi CQX, Sinusas AJ, Dione DP, Singer MJ, Young LH, Heller EN, et al. Technetium-99m-nitrimidazole (BMS181321): a positive imaging agent for detecting myocardial ischemia. J Nucl Med 1995;36:1078–86.PubMed

117.

Rumsey WL, Kuczynski B, Patel B, Bauer A, Narra RK, Eaton SM, et al. SPECT imaging of ischemic myocardium using a technetium-99m-nitroimidazole ligand. J Nucl Med 1995;36:1445–50.PubMed

118.

Fukuchi K, Kusuoka H, Watanabe Y, Fujiwara T, Nishimura T. Ischemic and reperfused myocardium detected with technetium-99m-nitroimidazole. J Nucl Med 1996;37:761–6.PubMed

119.

Ballinger JR, Kee JWM, Rauth AM. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med 1996;37:1023–31.PubMed

120.

Melo T, Duncan J, Ballinger JR, Rauth AM. BRU59–21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med 2000;41:169–76.PubMed

121.

Zhang X, Melo T, Rauth AM, Ballinger JR. Cellular accumulation and retention of the technetium-99m-labelled hypoxia markers BRU59–21 and butylene amine oxime. Nucl Med Biol 2001;28:949–57.PubMedCrossRef

122.

Hoebers FJP, Janssen HLK, Olmos RAV, Sprong D, Nunn AD, Balm AJM, et al. Phase 1 study to identify tumour hypoxia in patients with head and neck cancer using technetium-99m BRU 59–21. Eur J Nucl Med Mol Imaging 2002;29:1206–11.PubMedCrossRef

123.

Zhang X, Melo T, Ballinger JR, Rauth AM. Studies of 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection. Int J Radiat Oncol Biol Phys 1998;42:737–40.PubMed

124.

Honess DJ, Hill SA, Collingridge DR, Edwards B, Brauers G, Powell NA, et al. Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo. Int J Radiat Oncol Biol Phys 1998;42:731–5.PubMed

125.

Yutani K, Kusuoka H, Fukuchi K, Tatsumi M, Nishimura T. Applicability of 99mTc-HL91, a putative hypoxic tracer, to detection of tumor hypoxia. J Nucl Med 1999;40:854–61.PubMed

126.

Tatsumi M, Yutani K, Kusuoka H, Nishimura T. Technetium-99m HL91 uptake as a tumour hypoxia marker: relationship to tumour blood flow. Eur J Nucl Med 1999;26:91–4.PubMedCrossRef

127.

Kinuya S, Yokoyama K, Konishi S, Li XF, Watanabe N, Shuke N, et al. Increased uptake of 99mTc-HL91 in tumor cells exposed to X-ray radiation. Ann Nucl Med 2000;14:139–41.PubMedCrossRef

128.

Siim BG, Laux WT, Rutland MD, Palmer BN, Wilson WR. Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2′-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Res 2000;60:4582–88.PubMed

129.

Suzuki T, Nakamura K, Kawase T, Kubo A. Biodistribution of hypoxic marker, 99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime) [in Japanese]. Kaku Igaku 2001;38:333–41.PubMed

130.

Suzuki T, Nakamura K, Kawase T, Kubo A. Monitoring of response to radiation therapy for human tumor xenografts using 99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime). Ann Nucl Med 2003;17:131–8.PubMedCrossRef

131.

Kinuya S, Yokoyama K, Li XF, Bai J, Watanabe N, Shuke N, et al. Hypoxia-induced alteration of tracer accumulation in cultured cancer cells and xenografts in mice: implications for pre-therapeutic prediction of treatment outcomes with (99m)Tc-sestamibi, (201)Tl chloride and (99m)Tc-HL91. Eur J Nucl Med Mol Imaging 2002;29:1006–11.PubMedCrossRef

132.

Lee BF, Chiu NT, Hsia CC, Shen LH. Accumulation of Tc-99m HL91 in tumor hypoxia: in vitro cell culture and in vivo tumor model. Kaohsiung J Med Sci 2008;24:461–72.PubMedCrossRef

133.

Cook GJR, Houston S, Barrington SF, Fogelman I. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med 1998;39:99–103.PubMed

134.

Van De Wiele C, Versijpt J, Dierckx RA, Moerman M, Lemmerling M, D’Asseler Y, et al. 99Tc(m) labelled HL91 versus computed tomography and biopsy for the visualization of tumour recurrence of squamous head and neck carcinoma. Nucl Med Commun 2001;22:269–75.CrossRef

135.

Li L, Yu J, Xing L, Ma F, Zhu H, Guo H, et al. Serial hypoxia imaging with 99mTc-HL91 SPECT to predict radiotherapy response in nonsmall cell lung cancer. Am J Clin Oncol 2006;29:628–33.PubMedCrossRef

Title: Molecular imaging of hypoxia with radiolabelled agents
Authors: Gilles Mees
Rudi Dierckx
Christel Vangestel
Christophe Van de Wiele
Publication date: 01-10-2009
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-009-1195-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Molecular imaging of hypoxia with radiolabelled agents

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2009

The predictive value of the renogram

Evaluation of left ventricular volumes and ejection fraction by gated SPECT and cardiac MRI in patients with dilated cardiomyopathy

Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT

Ethan J. Halpner (ed): Clinical cardiac CT

Quantitative relationship between coronary calcium content and coronary flow reserve as assessed by integrated PET/CT imaging

Radiation dosimetry and biodistribution of 99mTc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer